Comment
doi: 10.1016/j.jinf.2023.11.008.
Epub 2023 Nov 21.
Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients
Affiliations
- PMID: 37992877
- DOI: 10.1016/j.jinf.2023.11.008
Item in Clipboard
Comment
Efficacy of SIGMAR1-based therapy in the early treatment of confirmed mild symptomatic COVID-19 patients
J Infect.
2024 Feb.
Free article
No abstract available
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no competing interests.
Comment on
-
There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use.J Infect. 2023 Feb;86(2):154-225. doi: 10.1016/j.jinf.2022.11.016. Epub 2022 Nov 25. J Infect. 2023. PMID: 36436621 Free PMC article. No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
